Abbott Laboratories (NYSE:ABT – Get Free Report) released its quarterly earnings results on Wednesday. The healthcare product maker reported $1.21 earnings per share for the quarter, beating the consensus estimate of $1.20 by $0.01, Briefing.com reports. The firm had revenue of $10.64 billion for the quarter, compared to analysts’ expectations of $10.55 billion. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.65%. The company’s revenue was up 4.9% compared to the same quarter last year. During the same quarter last year, the firm posted $1.14 EPS.
Abbott Laboratories Price Performance
ABT opened at $117.82 on Thursday. The company has a market capitalization of $204.96 billion, a price-to-earnings ratio of 36.70, a PEG ratio of 2.74 and a beta of 0.72. The company has a current ratio of 1.68, a quick ratio of 1.18 and a debt-to-equity ratio of 0.33. Abbott Laboratories has a 12-month low of $91.25 and a 12-month high of $121.64. The business’s fifty day simple moving average is $113.60 and its 200-day simple moving average is $108.40.
Abbott Laboratories Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 15th. Investors of record on Tuesday, October 15th will be paid a $0.55 dividend. The ex-dividend date of this dividend is Tuesday, October 15th. This represents a $2.20 annualized dividend and a yield of 1.87%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 68.54%.
Analyst Ratings Changes
Check Out Our Latest Stock Report on ABT
Insider Activity at Abbott Laboratories
In other Abbott Laboratories news, CEO Robert B. Ford sold 141,679 shares of the stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $116.41, for a total transaction of $16,492,852.39. Following the transaction, the chief executive officer now directly owns 220,059 shares in the company, valued at $25,617,068.19. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.10% of the stock is currently owned by corporate insiders.
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Further Reading
- Five stocks we like better than Abbott Laboratories
- Industrial Products Stocks Investing
- Should Warren Buffett’s Favorite Stock be Yours Too?
- The How And Why of Investing in Oil Stocks
- Why Buffett Loves Occidental Stock And What It Means for Chevron
- What Investors Need to Know to Beat the Market
- UnitedHealth Group Pulls Back Into a Healthy Buying Opportunity
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.